Medigen Biotechnology Corp. (3176.TWO)
TWD 31.7
(-0.94%)
TWD 31.7
(-0.94%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -569.4 Million | -1.12 Billion | 517.45 Million | -671.38 Million | -560.16 Million | -529.81 Million |
| Net Income | -561.29 Million | -675.87 Million | -52.61 Million | -337.92 Million | -328.88 Million | -422.91 Million |
| Depreciation & Amortization | 178.38 Million | 191.64 Million | 198.42 Million | 218.84 Million | 213.45 Million | 211.87 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 22.36 Million | 82.06 Million | 77.39 Million | 54.87 Million | - | - |
| Change in working capital | 444.05 Million | 175.26 Million | -953.99 Million | -95.57 Million | -52.61 Million | 62.58 Million |
| Other non-cash items | -405.27 Million | -910.45 Million | 2.72 Billion | 127.29 Million | 131.71 Million | 29.94 Million |
| Investing Cash Flow | 667.6 Million | -692.66 Million | -369.75 Million | 2.07 Billion | 790.37 Million | -74 Million |
| Investments in PPE | -50.91 Million | -151.37 Million | -144.54 Million | -140.29 Million | -113.84 Million | -124.12 Million |
| Acquisitions | 212.86 Million | 1.76 Billion | 666.75 Million | 2.33 Billion | 351.28 Million | 607.93 Million |
| Investment purchases | -3.34 Billion | -3.07 Billion | -2 Billion | -429.69 Million | -375.41 Million | -544.03 Million |
| Sales/Maturities of investments | 3.76 Billion | 800 Million | 1.12 Billion | 325.2 Million | 941.29 Million | 7.15 Million |
| Other Investing Activities | 88.32 Million | -22.27 Million | -12.25 Million | -16.95 Million | -12.93 Million | -20.93 Million |
| Financing Cash Flow | 35.13 Million | 1.72 Billion | -209.29 Million | -33.44 Million | 66.4 Million | 1.13 Million |
| Debt repayment | -106.01 Million | -1.76 Billion | -190.54 Million | -385.94 Million | -20.53 Million | -39.09 Million |
| Dividends payments | -37.55 Million | -30.04 Million | - | - | - | - |
| Common Stock Repurchased | -18.59 Million | - | - | - | - | - |
| Common Stock Issuance | 3.28 Million | 2.41 Million | 11.27 Million | 4.44 Million | - | - |
| Other Financing Activities | -37.55 Million | -26.73 Million | -23.18 Million | 360.73 Million | 57.75 Million | 40.22 Million |
| Accounts receivables | 59.94 Million | 383.95 Million | -631.95 Million | 2.1 Million | -92.39 Million | 27.13 Million |
| Accounts payables | -74.37 Million | 30.79 Million | 53.82 Million | 39.09 Million | -32 Thousand | -13.68 Million |
| Inventory | 145.92 Million | 60.29 Million | -429.01 Million | -187.53 Million | -4.5 Million | -1 Million |
| Other working capital | 312.55 Million | -299.76 Million | 53.14 Million | 50.76 Million | 44.32 Million | 50.13 Million |
| Cash at beginning of period | 2.04 Billion | 2.14 Billion | 2.2 Billion | 813.69 Million | 590.76 Million | 1.17 Billion |
| Cash at end of period | 2.22 Billion | 2.04 Billion | 2.14 Billion | 2.2 Billion | 813.69 Million | 590.76 Million |
| Capital Expenditure | -50.91 Million | -151.37 Million | -144.54 Million | -140.29 Million | -113.84 Million | -124.12 Million |
| Effect of forex changes on cash | -5 Million | -3.07 Million | -964 Thousand | 6.34 Million | - | - |
| Net cash flow / Change in cash | 182.29 Million | -103.94 Million | -61.99 Million | 1.39 Billion | 222.92 Million | -582.04 Million |
| Free Cash Flow | -620.32 Million | -1.27 Billion | 372.9 Million | -811.67 Million | -674.01 Million | -653.94 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 11.94 Million | -75.74 Million | -561.29 Million | -322.16 Million | -47.1 Million | -97.33 Million |
| Depreciation & Amortization | 43.23 Million | 44.13 Million | 178.38 Million | 44.03 Million | 44.34 Million | 45.22 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 238 Thousand | 2.21 Million | 22.36 Million | 6.46 Million | -3.25 Million | 13.94 Million |
| Change in working capital | -74.05 Million | -9.84 Million | 444.05 Million | 478.24 Million | -63.09 Million | -84.01 Million |
| Other non-cash items | 208.96 Million | 63.26 Million | -405.27 Million | -715.42 Million | 251.8 Million | 236.37 Million |
| Investing Cash Flow | -558.38 Million | 2.04 Billion | 667.6 Million | 841.78 Million | 81.84 Million | 107.42 Million |
| Investments in PPE | -15.73 Million | -15.22 Million | -50.91 Million | 53.59 Million | -12.2 Million | -66.61 Million |
| Acquisitions | 1.41 Million | 1.11 Million | 212.86 Million | 35.22 Million | 106.42 Million | 63.09 Million |
| Investment purchases | -701.73 Million | -285.38 Million | -3.34 Billion | -10.53 Million | -12.1 Million | 15.64 Million |
| Sales/Maturities of investments | - | 2.34 Billion | 3.76 Billion | 746.04 Million | 303 Thousand | 39.99 Million |
| Other Investing Activities | 157.66 Million | 1.86 Million | 88.32 Million | 17.45 Million | -573 Thousand | 55.31 Million |
| Financing Cash Flow | -1.78 Billion | 33.5 Million | 35.13 Million | 78.39 Million | -169.01 Million | 87.14 Million |
| Debt repayment | -1.88 Billion | -10.14 Million | -106.01 Million | -92.26 Million | -56.12 Million | -61.68 Million |
| Dividends payments | - | - | -37.55 Million | - | - | - |
| Common Stock Repurchased | - | - | -18.59 Million | -12.39 Million | - | -6.19 Million |
| Common Stock Issuance | - | - | 3.28 Million | 3.28 Million | - | - |
| Other Financing Activities | 106.17 Million | 48.2 Million | -37.55 Million | 36.99 Million | -99.62 Million | 27.4 Million |
| Accounts receivables | -115.03 Million | 91.93 Million | 59.94 Million | 71.87 Million | -200.06 Million | -51.45 Million |
| Accounts payables | -7.58 Million | -6.23 Million | -74.37 Million | 27.48 Million | -32.02 Million | 11.14 Million |
| Inventory | -67.93 Million | -24.44 Million | 145.92 Million | 452.75 Million | 39.64 Million | -339.58 Million |
| Other working capital | 116.5 Million | -71.1 Million | 312.55 Million | -73.86 Million | 129.35 Million | 295.86 Million |
| Cash at beginning of period | 4.3 Billion | 2.22 Billion | 2.04 Billion | 1.26 Billion | 1.47 Billion | 1.71 Billion |
| Cash at end of period | 1.87 Billion | 4.3 Billion | 2.22 Billion | 2.22 Billion | 1.26 Billion | 1.47 Billion |
| Capital Expenditure | -15.73 Million | -15.22 Million | -50.91 Million | 53.59 Million | -12.2 Million | -66.61 Million |
| Effect of forex changes on cash | -2.13 Million | 3.38 Million | -5 Million | 37.65 Million | -28.71 Million | -11.42 Million |
| Net cash flow / Change in cash | -2.43 Billion | 2.08 Billion | 182.29 Million | 960.51 Million | -211.08 Million | -240.6 Million |
| Free Cash Flow | -102.66 Million | -20.42 Million | -620.32 Million | 2.32 Million | -107.4 Million | -436.7 Million |
NHC
BCIC
4537
ALRPD
0ROQ
CINDRELL